Peter Stenvinkel

List of Publications by Citations

Source: https://exaly.com/author-pdf/6599639/peter-stenvinkel-publications-by-citations.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

579 papers	32,583 citations	91 h-index	158 g-index
640 ext. papers	37,388 ext. citations	5.5 avg, IF	7.3 L-index

#	Paper	IF	Citations
579	Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. *Kidney International*, **1999**, 55, 1899-911	9.9	1196
578	Review on uremic toxins: classification, concentration, and interindividual variability. *Kidney International*, **2003**, 63, 1934-43	9.9	1067
577	The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. *Kidney International*, **2002**, 62, 1524-38	9.9	846
576	Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). *Nephrology Dialysis Transplantation*, **2000**, 15, 953-60	4.3	599
575	IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly. *Kidney International*, **2005**, 67, 1216-33	9.9	588
574	Aspects of immune dysfunction in end-stage renal disease. *Clinical Journal of the American Society of Nephrology: CJASN*, **2008**, 3, 1526-33	6.9	580
573	Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. *Nephrology Dialysis Transplantation*, **2003**, 18, 1272-80	4.3	540
572	Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. *Lancet, The*, **2017**, 390, 1888-1917	40	419
571	Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). *Journal of Renal Nutrition*, **2013**, 23, 77-90	3	407
570	The malnutrition, inflammation, and atherosclerosis (MIA) syndrome -- the heart of the matter. *Nephrology Dialysis Transplantation*, **2002**, 17 Suppl 11, 28-31	4.3	405
569	Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?. *Clinical Journal of the American Society of Nephrology: CJASN*, **2008**, 3, 505-21	6.9	380
568	Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. *American Journal of Kidney Diseases*, **2006**, 47, 139-48	7.4	371
567	Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism. *Kidney International*, **2013**, 84, 1096-107	9.9	348
566	Associations between circulating inflammatory markers and residual renal function in CRF patients. *American Journal of Kidney Diseases*, **2003**, 41, 1212-8	7.4	319
565	Impact of inflammation on epigenetic DNA methylation - a novel risk factor for cardiovascular disease?. *Journal of Internal Medicine*, **2007**, 261, 488-99	10.8	304
564	Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. *Nephrology Dialysis Transplantation*, **2002**, 17, 1684-8	4.3	290
563	Inflammation in end-stage renal disease: sources, consequences, and therapy. *Seminars in Dialysis*, **2002**, 15, 329-37	2.5	286

562	Hemoglobin variability does not predict mortality in European hemodialysis patients. *Journal of the American Society of Nephrology: JASN*, **2010**, 21, 1765-75	12.7	262
561	Comparative associations of muscle mass and muscle strength with mortality in dialysis patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2014**, 9, 1720-8	6.9	259
560	Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. *Kidney International*, **2005**, 67, 2383-92	9.9	232
559	Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. *Journal of Internal Medicine*, **2010**, 268, 456-67	10.8	229
558	Chronic kidney disease and premature ageing. *Nature Reviews Nephrology*, **2014**, 10, 732-42	14.9	215
557	Inflammation in end-stage renal disease--what have we learned in 10 years?. *Seminars in Dialysis*, **2010**, 23, 498-509	2.5	213
556	Uremic Toxicity: Present State of the Art. *International Journal of Artificial Organs*, **2001**, 24, 695-725	1.9	209
555	Genetic loci influencing kidney function and chronic kidney disease. *Nature Genetics*, **2010**, 42, 373-5	36.3	205
554	Obese sarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality. *American Journal of Clinical Nutrition*, **2007**, 86, 633-8	7	204
553	Hand-grip muscle strength, lean body mass, and plasma proteins as markers of nutritional status in patients with chronic renal failure close to start of dialysis therapy. *American Journal of Kidney Diseases*, **2000**, 36, 1213-25	7.4	203
552	Muscle atrophy, inflammation and clinical outcome in incident and prevalent dialysis patients. *Clinical Nutrition*, **2008**, 27, 557-64	5.9	185
551	Serum Trimethylamine-N-Oxide Is Strongly Related to Renal Function and Predicts Outcome in Chronic Kidney Disease. *PLoS ONE*, **2016**, 11, e0141738	3.7	185
550	Climate Change and the Emergent Epidemic of CKD from Heat Stress in Rural Communities: The Case for Heat Stress Nephropathy. *Clinical Journal of the American Society of Nephrology: CJASN*, **2016**, 11, 1472-83	6.9	185
549	Chronic kidney disease: a clinical model of premature aging. *American Journal of Kidney Diseases*, **2013**, 62, 339-51	7.4	184
548	Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. *American Journal of Clinical Nutrition*, **2007**, 85, 695-701	7	182
547	Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. *Journal of the American Society of Nephrology: JASN*, **2003**, 14, 1927-39	12.7	182
546	Consequences of low plasma histidine in chronic kidney disease patients: associations with inflammation, oxidative stress, and mortality. *American Journal of Clinical Nutrition*, **2008**, 87, 1860-6	7	180
545	J-shaped mortality relationship for uric acid in CKD. *American Journal of Kidney Diseases*, **2006**, 48, 761-71	7.4	172

544	Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. *Kidney International*, **2006**, 69, 596-604	9.9	168
543	Inflammatory and atherosclerotic interactions in the depleted uremic patient. *Blood Purification*, **2001**, 19, 53-61	3.1	168
542	Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumoniae seropositivity. *American Journal of Kidney Diseases*, **2002**, 39, 274-82	7.4	167
541	Wasting in chronic kidney disease. *Journal of Cachexia, Sarcopenia and Muscle*, **2011**, 2, 9-25	10.3	160
540	Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. *Nephrology Dialysis Transplantation*, **2002**, 17, 1480-6	4.3	160
539	Truncal fat mass as a contributor to inflammation in end-stage renal disease. *American Journal of Clinical Nutrition*, **2004**, 80, 1222-9	7	159
538	Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. *Journal of the American Society of Nephrology: JASN*, **1997**, 8, 1423-30	12.7	154
537	Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. *Kidney International*, **2000**, 57, 1727-35	9.9	145
536	Screening for muscle wasting and dysfunction in patients with chronic kidney disease. *Kidney International*, **2016**, 90, 53-66	9.9	141
535	Inflammation in end-stage renal disease: the hidden enemy. *Nephrology*, **2006**, 11, 36-41	2.2	140
534	Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: association with malnutrition, inflammation, and cardiovascular disease. *Nephrology Dialysis Transplantation*, **2000**, 15, 1624-30	4.3	140
533	Low serum testosterone increases mortality risk among male dialysis patients. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 613-20	12.7	138
532	Increases in serum leptin levels during peritoneal dialysis are associated with inflammation and a decrease in lean body mass. *Journal of the American Society of Nephrology: JASN*, **2000**, 11, 1303-1309	12.7	138
531	Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal. *Clinical Journal of the American Society of Nephrology: CJASN*, **2009**, 4 Suppl 1, S49-55	6.9	137
530	Telomere attrition is associated with inflammation, low fetuin-A levels and high mortality in prevalent haemodialysis patients. *Journal of Internal Medicine*, **2008**, 263, 302-12	10.8	137
529	Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage?. *Kidney International*, **2002**, 62, 1791-8	9.9	137
528	A comparative analysis of nutritional parameters as predictors of outcome in male and female ESRD patients. *Nephrology Dialysis Transplantation*, **2002**, 17, 1266-74	4.3	136
527	Obesity in CKD--what should nephrologists know?. *Journal of the American Society of Nephrology: JASN*, **2013**, 24, 1727-36	12.7	134

526	Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6?. *Kidney International*, **2002**, 103-8	9.9	134
525	Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD. *Nature Reviews Nephrology*, **2017**, 13, 429-442	14.9	130
524	Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. *Kidney International*, **2004**, 65, 274-81	9.9	125
523	Multinutrient oral supplements and tube feeding in maintenance dialysis: a systematic review and meta-analysis. *American Journal of Kidney Diseases*, **2005**, 46, 387-405	7.4	125
522	Nutritional strategies to modulate inflammation and oxidative stress pathways via activation of the master antioxidant switch Nrf2. *Biochimie*, **2013**, 95, 1525-33	4.6	124
521	Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. *Clinical Journal of the American Society of Nephrology: CJASN*, **2007**, 2, 889-97	6.9	124
520	Accelerated lean body mass loss in incident chronic dialysis patients with diabetes mellitus. *Kidney International*, **2005**, 68, 2368-74	9.9	123
519	Low leptin gene expression and hyperleptinemia in chronic renal failure. *Kidney International*, **1998**, 54, 1267-75	9.9	122
518	Inflammation and premature aging in advanced chronic kidney disease. *American Journal of Physiology - Renal Physiology*, **2017**, 313, F938-F950	4.3	121
517	Diets and enteral supplements for improving outcomes in chronic kidney disease. *Nature Reviews Nephrology*, **2011**, 7, 369-84	14.9	119
516	Malnutrition and chronic inflammation as risk factors for cardiovascular disease in chronic renal failure. *Blood Purification*, **2001**, 19, 143-51	3.1	119
515	Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. *Journal of the American Society of Nephrology: JASN*, **2003**, 14, 1614-22	12.7	117
514	Homocysteine in uraemia--a puzzling and conflicting story. *Nephrology Dialysis Transplantation*, **2005**, 20, 16-21	4.3	116
513	Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis. *Nephrology Dialysis Transplantation*, **2001**, 16, 2240-5	4.3	113
512	Chronic inflammation in end-stage renal disease and dialysis. *Nephrology Dialysis Transplantation*, **2018**, 33, iii35-iii40	4.3	113
511	Sex and gender differences in chronic kidney disease: progression to end-stage renal disease and haemodialysis. *Clinical Science*, **2016**, 130, 1147-63	6.5	112
510	Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. *Nephrology Dialysis Transplantation*, **2011**, 26, 184-90	4.3	109
509	Serum albumin as predictor of nutritional status in patients with ESRD. *Clinical Journal of the American Society of Nephrology: CJASN*, **2012**, 7, 1446-53	6.9	109

508	Inflammation in end-stage renal failure: could it be treated?. *Nephrology Dialysis Transplantation*, **2002**, 17 Suppl 8, 33-8; discussion 40	4.3	109
507	Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. *JAMA - Journal of the American Medical Association*, **2014**, 311, 919-28	27.4	104
506	Clinical and biochemical implications of low thyroid hormone levels (total and free forms) in euthyroid patients with chronic kidney disease. *Journal of Internal Medicine*, **2007**, 262, 690-701	10.8	102
505	Associations between plasma ghrelin levels and body composition in end-stage renal disease: a longitudinal study. *Nephrology Dialysis Transplantation*, **2004**, 19, 421-6	4.3	97
504	The role of oxidative stress in chronic kidney disease. *Seminars in Dialysis*, **2009**, 22, 405-8	2.5	96
503	Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2008**, 3, 61-8	6.9	96
502	Association between residual renal function, inflammation and patient survival in new peritoneal dialysis patients. *Nephrology Dialysis Transplantation*, **2003**, 18, 590-7	4.3	95
501	Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. *Scandinavian Journal of Urology and Nephrology*, **2004**, 38, 405-16		95
500	Muscle wasting in end-stage renal disease promulgates premature death: established, emerging and potential novel treatment strategies. *Nephrology Dialysis Transplantation*, **2016**, 31, 1070-7	4.3	94
499	Why cachexia kills: examining the causality of poor outcomes in wasting conditions. *Journal of Cachexia, Sarcopenia and Muscle*, **2013**, 4, 89-94	10.3	94
498	Abdominal fat deposition is associated with increased inflammation, protein-energy wasting and worse outcome in patients undergoing haemodialysis. *Nephrology Dialysis Transplantation*, **2010**, 25, 562-8	4.3	94
497	Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival. *American Journal of Kidney Diseases*, **2009**, 53, 1024-33	7.4	94
496	Do ACE-inhibitors suppress tumour necrosis factor-alpha production in advanced chronic renal failure?. *Journal of Internal Medicine*, **1999**, 246, 503-7	10.8	94
495	Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2009**, 4, 110-8	6.9	93
494	A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. *Kidney International*, **2003**, S172-6	9.9	93
493	Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. *Clinical Journal of the American Society of Nephrology: CJASN*, **2008**, 3, 976-85	6.9	92
492	Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. *American Journal of Kidney Diseases*, **2007**, 49, 237-44	7.4	92
491	Biomarkers of Cardiovascular Disease and Mortality Risk in Patients with Advanced CKD. *Clinical Journal of the American Society of Nephrology: CJASN*, **2016**, 11, 1163-72	6.9	91

490	Systemic consequences of poor oral health in chronic kidney disease patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2011**, 6, 218-26	6.9	91
489	Adipose tissue and its relation to inflammation: the role of adipokines. *Journal of Renal Nutrition*, **2005**, 15, 131-6	3	91
488	Influence of Peritoneal Transport Rate, Inflammation, and Fluid Removal on Nutritional Status and Clinical Outcome in Prevalent Peritoneal Dialysis Patients. *Peritoneal Dialysis International*, **2003**, 23, 174-183	2.8	91
487	Increased muscle protein breakdown in chronic hemodialysis patients with type 2 diabetes mellitus. *Kidney International*, **2005**, 68, 1857-65	9.9	89
486	Systemic and Intraperitoneal Interleukin-6 System during the First Year of Peritoneal Dialysis. *Peritoneal Dialysis International*, **2006**, 26, 53-63	2.8	88
485	Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes. *Nephrology Dialysis Transplantation*, **2011**, 26, 3537-43	4.3	87
484	Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. *Nephrology Dialysis Transplantation*, **2008**, 23, 959-65	4.3	87
483	Genetic and clinical factors influence the baseline permeability of the peritoneal membrane. *Kidney International*, **2005**, 67, 2477-87	9.9	87
482	Effects of insulin on renal haemodynamics and the proximal and distal tubular sodium handling in healthy subjects. *Diabetologia*, **1992**, 35, 1042-8	10.3	87
481	Serum leptin concentrations correlate to plasma insulin concentrations independent of body fat content in chronic renal failure. *Nephrology Dialysis Transplantation*, **1997**, 12, 1321-5	4.3	85
480	Monitoring of inflammation in patients on dialysis: forewarned is forearmed. *Nature Reviews Nephrology*, **2011**, 7, 166-76	14.9	84
479	Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. *Kidney International*, **2015**, 88, 1356-1364	9.9	83
478	Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease. *Clinical Journal of the American Society of Nephrology: CJASN*, **2011**, 6, 1617-25	6.9	83
477	Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. *Nephrology Dialysis Transplantation*, **2008**, 23, 1621-7	4.3	81
476	Circulating inflammatory endothelial cells contribute to endothelial progenitor cell dysfunction in patients with vasculitis and kidney involvement. *Journal of the American Society of Nephrology: JASN*, **2005**, 16, 3110-20	12.7	81
475	Inflammation as a risk factor and target for therapy in chronic kidney disease. *Current Opinion in Nephrology and Hypertension*, **2011**, 20, 662-8	3.5	80
474	Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease. *Nephrology Dialysis Transplantation*, **2012**, 27, 70-5	4.3	80
473	Inflammation and nutrition in renal insufficiency. *Advances in Chronic Kidney Disease*, **2003**, 10, 155-69		78

472	MO069SARS-COV-2 RECEPTOR ACE-2, TMPRSS2 AND SOLUBLE ACE-2 IN PATIENTS WITH END STAGE KIDNEY DISEASE. *Nephrology Dialysis Transplantation*, **2021**, 36,	4.3	78
471	Cytokine dysregulation in chronic kidney disease: how can we treat it?. *Blood Purification*, **2008**, 26, 291-9	3.1	76
470	High Mobility Group Box Protein-1 correlates with renal function in chronic kidney disease (CKD). *Molecular Medicine*, **2008**, 14, 109-15	6.2	76
469	Chronic Inflammation in Peritoneal Dialysis: The Search for the Holy Grail?. *Peritoneal Dialysis International*, **2004**, 24, 327-339	2.8	76
468	Malnutrition, Inflammation, and Atherosclerosis in Peritoneal Dialysis Patients. *Peritoneal Dialysis International*, **2001**, 21, 157-162	2.8	76
467	Appetite disorders in uremia. *Journal of Renal Nutrition*, **2008**, 18, 107-13	3	75
466	High cardiovascular event rates occur within the first weeks of starting hemodialysis. *Kidney International*, **2015**, 88, 1117-25	9.9	74
465	Low serum uric acid level is a risk factor for death in incident hemodialysis patients. *American Journal of Nephrology*, **2009**, 29, 79-85	4.6	72
464	Therapeutics targeting persistent inflammation in chronic kidney disease. *Translational Research*, **2016**, 167, 204-13	11	70
463	Inflammation Modifies the Paradoxical Association between Body Mass Index and Mortality in Hemodialysis Patients. *Journal of the American Society of Nephrology: JASN*, **2016**, 27, 1479-86	12.7	70
462	ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 388-95	12.7	70
461	Cytokine gene polymorphism and progression of renal and cardiovascular diseases. *Kidney International*, **2007**, 72, 549-56	9.9	69
460	Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. *Clinical Journal of the American Society of Nephrology: CJASN*, **2012**, 7, 207-15	6.9	67
459	Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure; links to inflammation and oxidative stress. *Nephrology Dialysis Transplantation*, **2002**, 17 Suppl 5, 32-7	4.3	67
458	Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2010**, 5, 2213-9	6.9	66
457	Inflammation in end-stage renal disease--a fire that burns within. *Contributions To Nephrology*, **2005** , 149, 185-199	1.6	65
456	Dietary Components That May Influence the Disturbed Gut Microbiota in Chronic Kidney Disease. *Nutrients*, **2019**, 11,	6.7	64
455	Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis patients. *American Journal of Kidney Diseases*, **2009**, 54, 1072-80	7.4	64

454	The role of epigenetics in renal ageing. *Nature Reviews Nephrology*, **2017**, 13, 471-482	14.9	62
453	Cytokines, atherogenesis, and hypercatabolism in chronic kidney disease: a dreadful triad. *Seminars in Dialysis*, **2009**, 22, 381-6	2.5	62
452	Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD. *American Journal of Kidney Diseases*, **2005**, 46, 628-34	7.4	62
451	Relation between serum fibroblast growth factor-23 level and mortality in incident dialysis patients: are gender and cardiovascular disease confounding the relationship?. *Nephrology Dialysis Transplantation*, **2010**, 25, 3033-8	4.3	61
450	A study of plasmalogen as an index of oxidative stress in patients with chronic renal failure. Evidence of increased oxidative stress in malnourished patients. *Nephrology Dialysis Transplantation*, **1998**, 13, 2594-600	4.3	61
449	Sarcopenia in chronic kidney disease: what have we learned so far?. *Journal of Nephrology*, **2021**, 34, 1347-8372	4.8	61
448	Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor-α are similarly associated with survival in haemodialysis patients. *Nephrology Dialysis Transplantation*, **2011**, 26, 1313-8	4.3	60
447	The vulnerable man: impact of testosterone deficiency on the uraemic phenotype. *Nephrology Dialysis Transplantation*, **2012**, 27, 4030-41	4.3	60
446	CCR5 deletion protects against inflammation-associated mortality in dialysis patients. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 1641-9	12.7	59
445	Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease. *Nephrology Dialysis Transplantation*, **2012**, 27, 709-15	4.3	59
444	Enhanced RAGE-mediated NFkappaB stimulation in inflamed hemodialysis patients. *Atherosclerosis*, **2005**, 180, 333-40	3.1	59
443	Interactions between inflammation, oxidative stress, and endothelial dysfunction in end-stage renal disease **2003**, 13, 144-8		59
442	High serum hyaluronan indicates poor survival in renal replacement therapy. *American Journal of Kidney Diseases*, **1999**, 34, 1083-8	7.4	58
441	Novel treatment strategies for chronic kidney disease: insights from the animal kingdom. *Nature Reviews Nephrology*, **2018**, 14, 265-284	14.9	57
440	Inflammation as a cause of malnutrition, atherosclerotic cardiovascular disease, and poor outcome in hemodialysis patients. *Hemodialysis International*, **2004**, 8, 118-29	1.7	57
439	Soluble leptin receptors and serum leptin in end-stage renal disease: relationship with inflammation and body composition. *European Journal of Clinical Investigation*, **2002**, 32, 811-7	4.6	57
438	Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. *Kidney International*, **1998**, 53, 1336-42	9.9	56
437	Inflammation contributes to low plasma amino acid concentrations in patients with chronic kidney disease. *American Journal of Clinical Nutrition*, **2005**, 82, 342-349	7	56

436	The higher mortality associated with low serum albumin is dependent on systemic inflammation in end-stage kidney disease. *PLoS ONE*, **2018**, 13, e0190410	3.7	54
435	Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): a rationale and study protocol. *Nephrology Dialysis Transplantation*, **2014**, 29, 1633-8	4.3	54
434	Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness **2009**, 2, i18-i26		54
433	Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria. *Clinical Journal of the American Society of Nephrology: CJASN*, **2009**, 4, 535-41	6.9	54
432	Soluble adhesion molecules in end-stage renal disease: a predictor of outcome. *Nephrology Dialysis Transplantation*, **2006**, 21, 1603-10	4.3	54
431	Inflammation and wasting in chronic kidney disease: Partners in crime. *Kidney International*, **2006**, 70, S8-S13	9.9	54
430	Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased cardiovascular mortality in patients on renal replacement therapy. *Nephrology Dialysis Transplantation*, **2004**, 19, 972-6	4.3	53
429	The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality. *QJM - Monthly Journal of the Association of Physicians*, **2008**, 101, 397-405	2.7	52
428	The prognostic impact of fluctuating levels of C-reactive protein in Brazilian haemodialysis patients: a prospective study. *Nephrology Dialysis Transplantation*, **2004**, 19, 2803-9	4.3	52
427	Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD. *American Journal of Kidney Diseases*, **2006**, 48, 916-25	7.4	51
426	Uremic toxicity: present state of the art. *International Journal of Artificial Organs*, **2001**, 24, 695-725	1.9	51
425	The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation. *Nephrology Dialysis Transplantation*, **2007**, 22, 209-17	4.3	50
424	Fat tissue accumulation during peritoneal dialysis is associated with a polymorphism in uncoupling protein 2. *Kidney International*, **2000**, 57, 1713-9	9.9	50
423	Inflammation and Premature Ageing in Chronic Kidney Disease. *Toxins*, **2020**, 12,	4.9	50
422	Protein-energy wasting modifies the association of ghrelin with inflammation, leptin, and mortality in hemodialysis patients. *Kidney International*, **2011**, 79, 749-56	9.9	49
421	Elevated serum levels of S-adenosylhomocysteine, but not homocysteine, are associated with cardiovascular disease in stage 5 chronic kidney disease patients. *Clinica Chimica Acta*, **2008**, 395, 106-10	6.2	49
420	C-reactive protein in end-stage renal disease: are there reasons to measure it?. *Blood Purification*, **2005**, 23, 72-8	3.1	49
419	Does statins promote vascular calcification in chronic kidney disease?. *European Journal of Clinical Investigation*, **2017**, 47, 137-148	4.6	48

418	Improvement of cardiac function after haemodialysis. Quantitative evaluation by colour tissue velocity imaging. *Nephrology Dialysis Transplantation*, **2004**, 19, 1497-506	4.3	48
417	Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose. *Nephron*, **1996**, 72, 135-44	3.3	48
416	Fruit and Vegetable Intake and Mortality in Adults undergoing Maintenance Hemodialysis. *Clinical Journal of the American Society of Nephrology: CJASN*, **2019**, 14, 250-260	6.9	47
415	Inflammation and Protein-Energy Wasting in the Uremic Milieu. *Contributions To Nephrology*, **2017**, 191, 58-71	1.6	47
414	Lipoprotein(a) in nephrotic syndrome. *Kidney International*, **1993**, 44, 1116-23	9.9	47
413	Inflammation contributes to low plasma amino acid concentrations in patients with chronic kidney disease. *American Journal of Clinical Nutrition*, **2005**, 82, 342-9	7	46
412	Resveratrol: why is it a promising therapy for chronic kidney disease patients?. *Oxidative Medicine and Cellular Longevity*, **2013**, 2013, 963217	6.7	45
411	New insights on inflammation in chronic kidney disease-genetic and non-genetic factors. *Nephrologie Et Therapeutique*, **2006**, 2, 111-9	0.6	45
410	Reduced gene expression of adiponectin in fat tissue from patients with end-stage renal disease. *Kidney International*, **2004**, 66, 46-50	9.9	45
409	Elevated cardiac troponin T in predialysis patients is associated with inflammation and predicts mortality. *Journal of Internal Medicine*, **2003**, 253, 153-60	10.8	45
408	Early Vascular Ageing and Cellular Senescence in Chronic Kidney Disease. *Computational and Structural Biotechnology Journal*, **2019**, 17, 721-729	6.8	44
407	Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients. *Nephrology Dialysis Transplantation*, **2015**, 30, 84-91	4.3	44
406	Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels. *Nephrology Dialysis Transplantation*, **2010**, 25, 901-6	4.3	44
405	Modification of the oxidative stress biomarker AOPP assay: application in uremic samples. *Clinica Chimica Acta*, **2008**, 393, 114-8	6.2	44
404	Redefining metabolic syndrome as a fat storage condition based on studies of comparative physiology. *Obesity*, **2013**, 21, 659-64	8	43
403	Low serum fetuin-A concentration predicts poor outcome only in the presence of inflammation in prevalent haemodialysis patients. *European Journal of Clinical Investigation*, **2008**, 38, 804-11	4.6	43
402	Role of fat mass and adipokines in chronic kidney disease. *Current Opinion in Nephrology and Hypertension*, **2008**, 17, 25-31	3.5	43
401	Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial activation. *Molecular Medicine*, **2009**, 15, 70-5	6.2	43

400	Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors. *Clinica Chimica Acta*, **2007**, 379, 87-94	6.2	43
399	Plasma sulfur amino acids in relation to cardiovascular disease, nutritional status, and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy. *American Journal of Kidney Diseases*, **2002**, 40, 480-8	7.4	43
398	Inflammation, malnutrition and atherosclerosis in end-stage renal disease: a global perspective. *Blood Purification*, **2002**, 20, 454-8	3.1	43
397	Eating During Hemodialysis Treatment: A Consensus Statement From the International Society of Renal Nutrition and Metabolism. *Journal of Renal Nutrition*, **2018**, 28, 4-12	3	43
396	Metabolic and Kidney Diseases in the Setting of Climate Change, Water Shortage, and Survival Factors. *Journal of the American Society of Nephrology: JASN*, **2016**, 27, 2247-56	12.7	42
395	Endogenous testosterone, muscle strength, and fat-free mass in men with chronic kidney disease. *Journal of Renal Nutrition*, **2013**, 23, e89-95	3	42
394	The emerging pleiotrophic role of adipokines in the uremic phenotype. *Current Opinion in Nephrology and Hypertension*, **2010**, 19, 37-42	3.5	42
393	The importance of diabetic nephropathy in current nephrological practice. *Nephrology Dialysis Transplantation*, **2003**, 18, 1716-25	4.3	42
392	Accelerated ageing and renal dysfunction links lower socioeconomic status and dietary phosphate intake. *Aging*, **2016**, 8, 1135-49	5.6	42
391	Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney International*, **2018**, 93, 1281-1292	9.9	41
390	Chronic systemic inflammation in dialysis patients: an update on causes and consequences. *ASAIO Journal*, **2004**, 50, lii-lvii	3.6	41
389	Effects of Probiotic Supplementation on Trimethylamine-N-Oxide Plasma Levels in Hemodialysis Patients: a Pilot Study. *Probiotics and Antimicrobial Proteins*, **2019**, 11, 648-654	5.5	41
388	Food as medicine: targeting the uraemic phenotype in chronic kidney disease. *Nature Reviews Nephrology*, **2021**, 17, 153-171	14.9	41
387	Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT. A novel marker of endothelial damage?. *Clinical Transplantation*, **2009**, 23, 241-8	3.8	40
386	Baseline levels and trimestral variation of triiodothyronine and thyroxine and their association with mortality in maintenance hemodialysis patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2012**, 7, 131-8	6.9	40
385	expression is associated with vascular progeria in chronic kidney disease. *Aging*, **2017**, 9, 494-507	5.6	40
384	Hibernating bears (Ursidae): metabolic magicians of definite interest for the nephrologist. *Kidney International*, **2013**, 83, 207-12	9.9	39
383	Inverse relationship between the inflammatory marker pentraxin-3, fat body mass, and abdominal obesity in end-stage renal disease. *Clinical Journal of the American Society of Nephrology: CJASN*, **2011**, 6, 2785-91	6.9	39

382	Klotho, Aging, and the Failing Kidney. *Frontiers in Endocrinology*, **2020**, 11, 560	5.7	39
381	Serum testosterone levels and clinical outcomes in male hemodialysis patients. *American Journal of Kidney Diseases*, **2014**, 63, 268-75	7.4	38
380	The complex role of adiponectin in chronic kidney disease. *Biochimie*, **2012**, 94, 2150-6	4.6	38
379	Essential polyunsaturated fatty acids, inflammation and mortality in dialysis patients. *Nephrology Dialysis Transplantation*, **2012**, 27, 3615-20	4.3	38
378	The role of the TGF/Smad signaling pathway in peritoneal fibrosis induced by peritoneal dialysis solutions. *Nephron Experimental Nephrology*, **2008**, 109, e71-8		38
377	Polymorphisms in cytokine genes influence long-term survival differently in elderly male and female patients. *Journal of Internal Medicine*, **2007**, 262, 215-23	10.8	38
376	Impact of residual renal function on volume status in chronic renal failure. *Blood Purification*, **2004**, 22, 285-92	3.1	38
375	Hyperhomocysteinemia and its relationship to cardiovascular disease in ESRD: influence of hypoalbuminemia, malnutrition, inflammation, and diabetes mellitus. *American Journal of Kidney Diseases*, **2003**, 41, S89-95	7.4	38
374	Clinical correlates of insulin sensitivity and its association with mortality among men with CKD stages 3 and 4. *Clinical Journal of the American Society of Nephrology: CJASN*, **2014**, 9, 690-7	6.9	37
373	Adiponectin in chronic kidney disease: a complex and context sensitive clinical situation. *Journal of Renal Nutrition*, **2011**, 21, 82-6	3	37
372	Increased expression of pro-inflammatory genes in abdominal subcutaneous fat in advanced chronic kidney disease patients. *Journal of Internal Medicine*, **2011**, 269, 410-9	10.8	37
371	Are insulin-like growth factor and its binding proteins 1 and 3 clinically useful as markers of malnutrition, sarcopenia and inflammation in end-stage renal disease?. *European Journal of Clinical Nutrition*, **2006**, 60, 718-26	5.2	37
370	Chronic kidney disease and inflammation in pediatric patients: from bench to playground. *Pediatric Nephrology*, **2005**, 20, 714-20	3.2	37
369	The relationship between IL-10 levels and cardiovascular events in patients with CKD. *Clinical Journal of the American Society of Nephrology: CJASN*, **2014**, 9, 1207-16	6.9	36
368	Metabolic changes in summer active and anuric hibernating free-ranging brown bears (Ursus arctos). *PLoS ONE*, **2013**, 8, e72934	3.7	36
367	Serum fetuin-a concentration and endothelial dysfunction in chronic kidney disease. *Nephron Clinical Practice*, **2008**, 108, c233-40		36
366	Risk Factors for Cardiovascular Disease in Patients Undergoing Peritoneal Dialysis. *Peritoneal Dialysis International*, **2007**, 27, 205-209	2.8	36
365	Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. *Peritoneal Dialysis International*, **2006**, 26, 53-63	2.8	36

364	Inflammatory biomarker pentraxin 3 (PTX3) in relation to obesity, body fat depots and weight loss. *Obesity*, **2014**, 22, 1373-9	8	35
363	Clinical importance of an elevated circulating chemerin level in incident dialysis patients. *Nephrology Dialysis Transplantation*, **2010**, 25, 4017-23	4.3	35
362	Elevated circulating levels and tissue expression of pentraxin 3 in uremia: a reflection of endothelial dysfunction. *PLoS ONE*, **2013**, 8, e63493	3.7	35
361	Clinical global assessment of nutritional status as predictor of mortality in chronic kidney disease patients. *PLoS ONE*, **2017**, 12, e0186659	3.7	35
360	Low-grade inflammation in chronic kidney disease patients before the start of renal replacement therapy: sources and consequences. *Clinical Nephrology*, **2007**, 68, 1-9	2.1	35
359	Understanding the role of the cytoprotective transcription factor nuclear factor erythroid 2-related factor 2-lessons from evolution, the animal kingdom and rare progeroid syndromes. *Nephrology Dialysis Transplantation*, **2020**, 35, 2036-2045	4.3	35
358	Circulating vascular endothelial growth factor (VEGF) and its soluble receptor 1 (sVEGFR-1) are associated with inflammation and mortality in incident dialysis patients. *Nephrology Dialysis Transplantation*, **2013**, 28, 2356-63	4.3	34
357	Malnutrition and inflammation are associated with impaired pulmonary function in patients with chronic kidney disease. *Nephrology Dialysis Transplantation*, **2004**, 19, 1823-8	4.3	34
356	Hyperhomocysteinemia in relation to plasma free amino acids, biomarkers of inflammation and mortality in patients with chronic kidney disease starting dialysis therapy. *American Journal of Kidney Diseases*, **2004**, 44, 455-465	7.4	34
355	Fructose metabolism as a common evolutionary pathway of survival associated with climate change, food shortage and droughts. *Journal of Internal Medicine*, **2020**, 287, 252-262	10.8	34
354	Early vascular ageing in chronic kidney disease: impact of inflammation, vitamin K, senescence and genomic damage. *Nephrology Dialysis Transplantation*, **2020**, 35, ii31-ii37	4.3	33
353	Curcumin - A promising nutritional strategy for chronic kidney disease patients. *Journal of Functional Foods*, **2018**, 40, 715-721	5.1	33
352	Clinical determinants of reduced physical activity in hemodialysis and peritoneal dialysis patients. *Journal of Nephrology*, **2015**, 28, 503-10	4.8	33
351	Hyperhomocysteinemia in uremia--a red flag in a disrupted circuit. *Seminars in Dialysis*, **2009**, 22, 351-6	2.5	33
350	Adipose tissue and inflammation in chronic kidney disease. *Contributions To Nephrology*, **2006**, 151, 165-174	1.4	33
349	Imbalance between detached circulating endothelial cells and endothelial progenitor cells in chronic kidney disease. *Blood Purification*, **2006**, 24, 196-202	3.1	33
348	Statin treatment and diabetes affect myeloperoxidase activity in maintenance hemodialysis patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2006**, 1, 281-7	6.9	33
347	Novel approaches in an integrated therapy of inflammatory-associated wasting in end-stage renal disease. *Seminars in Dialysis*, **2004**, 17, 505-15	2.5	33

346	Molecular studies of leptin: implications for renal disease. *Nephrology Dialysis Transplantation*, **1999**, 14, 1103-12	4.3	33
345	Impact of curcumin supplementation on expression of inflammatory transcription factors in hemodialysis patients: A pilot randomized, double-blind, controlled study. *Clinical Nutrition*, **2020**, 39, 3594-3600	5.9	32
344	MicroRNAs in AKI and Kidney Transplantation. *Clinical Journal of the American Society of Nephrology: CJASN*, **2019**, 14, 454-468	6.9	32
343	Circulating markers of ageing and allostatic load: A slow train coming. *Practical Laboratory Medicine*, **2017**, 7, 49-54	1.7	31
342	Nrf2 in early vascular ageing: Calcification, senescence and therapy. *Clinica Chimica Acta*, **2020**, 505, 108-18	6.18	31
341	Leptin, ghrelin, and proinflammatory cytokines: compounds with nutritional impact in chronic kidney disease?. *Advances in Chronic Kidney Disease*, **2003**, 10, 332-45		31
340	Kidney insufficiency and nutrient-based modulation of inflammation. *Current Opinion in Clinical Nutrition and Metabolic Care*, **2005**, 8, 388-96	3.8	31
339	Adverse Pregnancy Outcomes and Long-term Maternal Kidney Disease: A Systematic Review and Meta-analysis. *JAMA Network Open*, **2020**, 3, e1920964	10.4	31
338	Red meat intake in chronic kidney disease patients: Two sides of the coin. *Nutrition*, **2018**, 46, 26-32	4.8	30
337	Nonthyroidal illness and the cardiorenal syndrome. *Nature Reviews Nephrology*, **2013**, 9, 599-609	14.9	30
336	Opposing activity changes in AMP deaminase and AMP-activated protein kinase in the hibernating ground squirrel. *PLoS ONE*, **2015**, 10, e0123509	3.7	30
335	Validation of insulin sensitivity surrogate indices and prediction of clinical outcomes in individuals with and without impaired renal function. *Kidney International*, **2014**, 86, 383-91	9.9	30
334	Impaired resistance artery function in patients with end-stage renal disease. *Clinical Science*, **2011**, 120, 525-36	6.5	30
333	Interleukin-6 is a better predictor of mortality as compared to C-reactive protein, homocysteine, pentosidine and advanced oxidation protein products in hemodialysis patients. *Blood Purification*, **2008**, 26, 204-10	3.1	30
332	Biocompatibility of New Peritoneal Dialysis Solutions: What Can We Hope to Achieve?. *Peritoneal Dialysis International*, **2000**, 20, 57-67	2.8	30
331	Mechanisms of endothelial dysfunction in resistance arteries from patients with end-stage renal disease. *PLoS ONE*, **2012**, 7, e36056	3.7	30
330	Adiponectin in chronic kidney disease has an opposite impact on protein-energy wasting and cardiovascular risk: two sides of the same coin. *Clinical Nephrology*, **2009**, 72, 87-96	2.1	30
329	Dialysis modality and nutritional status are associated with variability of inflammatory markers. *Nephrology Dialysis Transplantation*, **2016**, 31, 1320-7	4.3	30

328	Development and validation of cardiovascular risk scores for haemodialysis patients. *International Journal of Cardiology*, **2016**, 216, 68-77	3.2	30
327	Oxidative DNA damage and mortality in hemodialysis and peritoneal dialysis patients. *Peritoneal Dialysis International*, **2015**, 35, 206-15	2.8	29
326	Serum fatty acid patterns, insulin sensitivity and the metabolic syndrome in individuals with chronic kidney disease. *Journal of Internal Medicine*, **2014**, 275, 71-83	10.8	29
325	Recent insights in inflammation-associated wasting in patients with chronic kidney disease. *Contributions To Nephrology*, **2011**, 171, 120-126	1.6	29
324	End-stage renal disease--not an equal opportunity disease: the role of genetic polymorphisms. *Journal of Internal Medicine*, **2005**, 258, 1-12	10.8	29
323	Clostridium difficile-associated diarrhoea in uremic patients. *European Journal of Clinical Microbiology and Infectious Diseases*, **1987**, 6, 352-6	5.3	29
322	Bone alkaline phosphatase: An important biomarker in chronic kidney disease - mineral and bone disorder. *Clinica Chimica Acta*, **2020**, 501, 198-206	6.2	29
321	Chronic inflammation in peritoneal dialysis: the search for the holy grail?. *Peritoneal Dialysis International*, **2004**, 24, 327-39	2.8	29
320	Genetic and environmental risk factors for chronic kidney disease. *Kidney International Supplements* , **2017**, 7, 88-106	6.3	28
319	Correlation of computed tomography with carotid plaque transcriptomes associates calcification with lesion-stabilization. *Atherosclerosis*, **2019**, 288, 175-185	3.1	28
318	Matrix Gla protein is an independent predictor of both intimal and medial vascular calcification in chronic kidney disease. *Scientific Reports*, **2020**, 10, 6586	4.9	28
317	Changes in fat mass after initiation of maintenance dialysis is influenced by the uncoupling protein 2 exon 8 insertion/deletion polymorphism. *Nephrology Dialysis Transplantation*, **2007**, 22, 196-202	4.3	28
316	Peroxisome proliferator-activated receptor gamma polymorphisms affect systemic inflammation and survival in end-stage renal disease patients starting renal replacement therapy. *Atherosclerosis*, **2005**, 182, 105-11	3.1	28
315	Nonthyroidal illness: a risk factor for coronary calcification and arterial stiffness in patients undergoing peritoneal dialysis?. *Journal of Internal Medicine*, **2013**, 274, 584-93	10.8	27
314	Dietary fat modification in patients with chronic kidney disease: n-3 fatty acids and beyond. *Journal of Nephrology*, **2013**, 26, 960-74	4.8	27
313	Serum soluble CD36, assessed by a novel monoclonal antibody-based sandwich ELISA, predicts cardiovascular mortality in dialysis patients. *Clinica Chimica Acta*, **2010**, 411, 2079-82	6.2	27
312	Anaemia and inflammation: what are the implications for the nephrologist?. *Nephrology Dialysis Transplantation*, **2003**, 18 Suppl 8, viii17-22	4.3	27
311	Renal hemodynamics and sodium handling in moderate renal insufficiency: the role of insulin resistance and dyslipidemia. *Journal of the American Society of Nephrology: JASN*, **1995**, 5, 1751-60	12.7	27

310	Vertebral bone density associates with coronary artery calcification and is an independent predictor of poor outcome in end-stage renal disease patients. *Bone*, **2016**, 92, 50-57	4.7	27
309	Preeclampsia and risk of end stage kidney disease: A Swedish nationwide cohort study. *PLoS Medicine*, **2019**, 16, e1002875	11.6	26
308	Obesity and nephrology: results of a knowledge and practice pattern survey. *Nephrology Dialysis Transplantation*, **2013**, 28 Suppl 4, iv99-104	4.3	26
307	Epicardial fat accumulation, cardiometabolic profile and cardiovascular events in patients with stages 3-5 chronic kidney disease. *Journal of Internal Medicine*, **2015**, 278, 77-87	10.8	26
306	Vascular calcification inhibitors in relation to cardiovascular disease with special emphasis on fetuin-A in chronic kidney disease. *Advances in Clinical Chemistry*, **2008**, 46, 217-62	5.8	26
305	Elevated serum 8-oxo-dG in hemodialysis patients: a marker of systemic inflammation?. *Antioxidants and Redox Signaling*, **2006**, 8, 2169-73	8.4	26
304	Effect of hepatitis C serology on C-reactive protein in a cohort of Brazilian hemodialysis patients. *Brazilian Journal of Medical and Biological Research*, **2005**, 38, 783-8	2.8	26
303	Chronic Inflammation in Chronic Kidney Disease Progression: Role of Nrf2. *Kidney International Reports*, **2021**, 6, 1775-1787	4.1	26
302	Associations of Chronic Inflammation, Insulin Resistance, and Severe Obesity With Mortality, Myocardial Infarction, Cancer, and Chronic Pulmonary Disease. *JAMA Network Open*, **2019**, 2, e1910456	10.4	25
301	Regional variations in the relationship between arterial stiffness and adipocyte volume or number in obese subjects. *International Journal of Obesity*, **2015**, 39, 222-7	5.5	25
300	Prevalence and Risk of Protein-Energy Wasting Assessed by Subjective Global Assessment in Older Adults With Advanced Chronic Kidney Disease: Results From the EQUAL Study. *Journal of Renal Nutrition*, **2018**, 28, 165-174	3	25
299	IGF-1 and survival in ESRD. *Clinical Journal of the American Society of Nephrology: CJASN*, **2014**, 9, 120-7	6.9	25
298	The role of EUTox in uremic toxin research. *Seminars in Dialysis*, **2009**, 22, 323-8	2.5	25
297	TOF-SIMS analysis of adipose tissue from patients with chronic kidney disease. *Applied Surface Science*, **2008**, 255, 1177-1180	6.7	25
296	Impaired intrarenal dopamine production following intravenous sodium chloride infusion in type 1 (insulin-dependent) diabetes mellitus. *Diabetologia*, **1991**, 34, 114-8	10.3	25
295	Low levels of IgM antibodies against phosphorylcholine-A increase mortality risk in patients undergoing haemodialysis. *Nephrology Dialysis Transplantation*, **2009**, 24, 3454-60	4.3	24
294	Circulating follistatin in patients with chronic kidney disease: implications for muscle strength, bone mineral density, inflammation, and survival. *Clinical Journal of the American Society of Nephrology: CJASN*, **2011**, 6, 1001-8	6.9	24
293	Low cholesterol in dialysis patients--causal factor for mortality or an effect of confounding?. *Nephrology Dialysis Transplantation*, **2011**, 26, 3325-31	4.3	24

292	Is fetuin-A/alpha2-Heremans-Schmid glycoprotein associated with the metabolic syndrome in patients with chronic kidney disease?. *American Journal of Nephrology*, **2008**, 28, 669-76	4.6	24
291	Genetic approaches in the clinical investigation of complex disorders: malnutrition, inflammation, and atherosclerosis (MIA) as a prototype. *Kidney International*, **2003**, S162-7	9.9	24
290	Leptin and its clinical implications in chronic renal failure. *Mineral and Electrolyte Metabolism*, **1999**, 25, 298-302		24
289	Whole genome DNA sequencing provides an atlas of somatic mutagenesis in healthy human cells and identifies a tumor-prone cell type. *Genome Biology*, **2019**, 20, 285	18.3	24
288	The G-protein coupled receptor ChemR23 determines smooth muscle cell phenotypic switching to enhance high phosphate-induced vascular calcification. *Cardiovascular Research*, **2019**, 115, 1557-1566	9.9	24
287	Circulating proteins as predictors of cardiovascular mortality in end-stage renal disease. *Journal of Nephrology*, **2019**, 32, 111-119	4.8	24
286	Allostatic load and ageing: linking the microbiome and nutrition with age-related health. *Biochemical Society Transactions*, **2019**, 47, 1165-1172	5.1	23
285	Associations between Thyroid Hormones, Calcification Inhibitor Levels and Vascular Calcification in End-Stage Renal Disease. *PLoS ONE*, **2015**, 10, e0132353	3.7	23
284	Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease. *Journal of Nephrology*, **2009**, 22, 774-82	4.8	23
283	Plasma fatty acids in chronic kidney disease: nervonic acid predicts mortality. *Journal of Renal Nutrition*, **2012**, 22, 277-283	3	22
282	Activity-related energy expenditure of patients undergoing hemodialysis. *Journal of Renal Nutrition* , **2011**, 21, 226-34	3	22
281	Is fetuin-A a mortality risk factor in dialysis patients or a mere risk marker? A Mendelian randomization approach. *Nephrology Dialysis Transplantation*, **2011**, 26, 239-45	4.3	22
280	Metabolic abnormalities in chronic kidney disease that contribute to cardiovascular disease, and nutritional initiatives that may diminish the risk. *Current Opinion in Lipidology*, **2009**, 20, 3-9	4.4	22
279	Plasma Pentosidine and Its Association with Mortality in Patients with Chronic Kidney Disease. *PLoS ONE*, **2016**, 11, e0163826	3.7	22
278	Nutritional status of older patients on hemodialysis: Which nutritional markers can best predict clinical outcomes?. *Nutrition*, **2019**, 65, 113-119	4.8	21
277	Senescent Cells in Early Vascular Ageing and Bone Disease of Chronic Kidney Disease-A Novel Target for Treatment. *Toxins*, **2019**, 11,	4.9	21
276	Cardiovascular biomarkers in chronic kidney disease. *Journal of Renal Nutrition*, **2012**, 22, 120-7	3	21
275	Associations of VEGF and its receptors sVEGFR-1 and -2 with cardiovascular disease and survival in prevalent haemodialysis patients. *Nephrology Dialysis Transplantation*, **2009**, 24, 3468-73	4.3	21

274	Interleukin-1 gene cluster polymorphisms are associated with nutritional status and inflammation in patients with end-stage renal disease. *Blood Purification*, **2005**, 23, 384-93	3.1	21
273	End-stage renal disease: a state of chronic inflammation and hyperleptinemia. *European Journal of Clinical Investigation*, **2003**, 33, 527-8	4.6	21
272	Biomimetics - Nature's roadmap to insights and solutions for burden of lifestyle diseases. *Journal of Internal Medicine*, **2020**, 287, 238-251	10.8	21
271	Subclinical versus overt obesity in dialysis patients: more than meets the eye. *Nephrology Dialysis Transplantation*, **2013**, 28 Suppl 4, iv175-81	4.3	20
270	Genetics/Genomics in chronic kidney disease--towards personalized medicine?. *Seminars in Dialysis*, **2009**, 22, 417-22	2.5	20
269	Gene polymorphism association studies in dialysis: the nutrition-inflammation axis. *Seminars in Dialysis*, **2005**, 18, 322-30	2.5	20
268	Total and bone-specific alkaline phosphatase are associated with bone mineral density over time in end-stage renal disease patients starting dialysis. *Journal of Nephrology*, **2017**, 30, 255-262	4.8	19
267	The microbial metabolite trimethylamine-N-oxide in association with inflammation and microbial dysregulation in three HIV cohorts at various disease stages. *Aids*, **2018**, 32, 1589-1598	3.5	19
266	Reduced skeletal muscle expression of mitochondrial-derived peptides humanin and MOTS-C and Nrf2 in chronic kidney disease. *American Journal of Physiology - Renal Physiology*, **2019**, 317, F1122-F1131	4.3	19
265	Influence of variation at the apolipoprotein E locus on lipid and lipoprotein levels in CAPD patients. *Nephrology Dialysis Transplantation*, **1997**, 12, 141-4	4.3	19
264	Why do dialysis patients develop a heart of stone and bone of china?. *Blood Purification*, **2005**, 23, 203-10	3.1	19
263	Effect of high-dose thiamine and pyridoxine on advanced glycation end products and other oxidative stress markers in hemodialysis patients: a randomized placebo-controlled study. *Journal of Renal Nutrition*, **2006**, 16, 119-24	3	19
262	What are the causes of protein-energy malnutrition in chronic renal insufficiency?. *American Journal of Kidney Diseases*, **2002**, 39, 422-5	7.4	19
261	Determinants and survival implications of low bone mineral density in end-stage renal disease patients. *Journal of Nephrology*, **2013**, 26, 485-94	4.8	19
260	Resolved: being fat is good for dialysis patients: the Godzilla effect: con. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 1062-4	12.7	19
259	Chemerin inhibits vascular calcification through ChemR23 and is associated with lower coronary calcium in chronic kidney disease. *Journal of Internal Medicine*, **2019**, 286, 449-457	10.8	18
258	Association between levels of pentraxin 3 and incidence of chronic kidney disease in the elderly. *Journal of Internal Medicine*, **2016**, 279, 173-9	10.8	18
257	Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation. *European Journal of Clinical Pharmacology*, **2012**, 68, 571-7	2.8	18

256	An epidemiological study of hemodialysis patients based on the European Fresenius Medical Care hemodialysis network: results of the ARO study. *Nephron Clinical Practice*, **2011**, 118, c143-54		18
255	Uraemic sera stimulate lipolysis in human adipocytes: role of perilipin. *Nephrology Dialysis Transplantation*, **2011**, 26, 2485-91	4.3	18
254	LDL-apheresis in patients with nephrotic syndrome: effects on serum albumin and urinary albumin excretion. *European Journal of Clinical Investigation*, **2000**, 30, 866-70	4.6	18
253	Influence of peritoneal transport rate, inflammation, and fluid removal on nutritional status and clinical outcome in prevalent peritoneal dialysis patients. *Peritoneal Dialysis International*, **2003**, 23, 174-83	2.8	18
252	Strategies to improve monitoring disease progression, assessing cardiovascular risk, and defining prognostic biomarkers in chronic kidney disease. *Kidney International Supplements*, **2017**, 7, 107-113	6.3	17
251	Obesity--a disease with many aetiologies disguised in the same oversized phenotype: has the overeating theory failed?. *Nephrology Dialysis Transplantation*, **2015**, 30, 1656-64	4.3	17
250	Can treating persistent inflammation limit protein energy wasting?. *Seminars in Dialysis*, **2013**, 26, 16-9	2.5	17
249	Rare progerin-expressing preadipocytes and adipocytes contribute to tissue depletion over time. *Scientific Reports*, **2017**, 7, 4405	4.9	17
248	Serum retinol-binding protein concentration and its association with components of the uremic metabolic syndrome in nondiabetic patients with chronic kidney disease stage 5. *American Journal of Nephrology*, **2009**, 29, 447-53	4.6	17
247	Temporal discrepancies in the association between the apoB/apoA-I ratio and mortality in incident dialysis patients. *Journal of Internal Medicine*, **2009**, 265, 708-16	10.8	17
246	Does the ob gene product leptin stimulate erythropoiesis in patients with chronic renal failure?. *Kidney International*, **1998**, 53, 1430-1	9.9	17
245	Bone mineral density in end-stage renal disease patients: association with wasting, cardiovascular disease and mortality. *Blood Purification*, **2008**, 26, 284-90	3.1	17
244	The influence of hepatitis C and iron replacement therapy on plasma pentosidine levels in haemodialysis patients. *Nephrology Dialysis Transplantation*, **2004**, 19, 3112-6	4.3	17
243	Molecular genetics in renal medicine: what can we hope to achieve?. *Nephrology Dialysis Transplantation*, **2002**, 17 Suppl 3, 5-11	4.3	17
242	Renal haemodynamics and tubular sodium handling following volume expansion with sodium chloride (NaCl) and glucose in healthy humans. *Scandinavian Journal of Clinical and Laboratory Investigation*, **1992**, 52, 837-46	2	17
241	Factors influencing progression in patients with chronic renal failure. *Journal of Internal Medicine*, **1989**, 226, 183-8	10.8	17
240	Long-lived animals with negligible senescence: clues for ageing research. *Biochemical Society Transactions*, **2019**, 47, 1157-1164	5.1	16
239	Self-rated appetite as a predictor of mortality in patients with stage 5 chronic kidney disease. *Journal of Renal Nutrition*, **2013**, 23, 106-13	3	16

238	N-terminal pro-brain natriuretic peptide independently predicts protein energy wasting and is associated with all-cause mortality in prevalent HD patients. *American Journal of Nephrology*, **2009**, 29, 516-23	4.6	16
237	Being an inflamed peritoneal dialysis patient - a Dante's journey. *Contributions To Nephrology*, **2006**, 150, 144-151	1.6	16
236	Low-density lipoprotein metabolism and its association to plasma lipoprotein(a) in the nephrotic syndrome. *European Journal of Clinical Investigation*, **1997**, 27, 169-77	4.6	16
235	Decreased renal clearance of sodium in cystic fibrosis. *Acta Paediatrica, International Journal of Paediatrics*, **1991**, 80, 194-8	3.1	16
234	Skin autofluorescence, arterial stiffness and Framingham risk score as predictors of clinical outcome in chronic kidney disease patients: a cohort study. *Nephrology Dialysis Transplantation*, **2019**, 34, 442-448	4.3	16
233	A distinct bone phenotype in ADPKD patients with end-stage renal disease. *Kidney International*, **2019**, 95, 412-419	9.9	15
232	Cranberries - potential benefits in patients with chronic kidney disease. *Food and Function*, **2019**, 10, 3103-3112	6.1	15
231	Health-related quality of life as predictor of mortality in end-stage renal disease patients: an observational study. *BMC Nephrology*, **2019**, 20, 144	2.7	15
230	The Association of Mediterranean and DASH Diets with Mortality in Adults on Hemodialysis: The DIET-HD Multinational Cohort Study. *Journal of the American Society of Nephrology: JASN*, **2018**, 29, 1741-1751	12.7	15
229	Bioactive food and exercise in chronic kidney disease: Targeting the mitochondria. *European Journal of Clinical Investigation*, **2018**, 48, e13020	4.6	15
228	Variations in C-reactive protein during a single haemodialysis session do not associate with mortality. *Nephrology Dialysis Transplantation*, **2010**, 25, 3717-23	4.3	15
227	DNA hypermethylation and inflammatory markers in incident Japanese dialysis patients. *Nephron Extra*, **2012**, 2, 159-68		15
226	Associations between the CYBA 242C/T and the MPO -463G/A polymorphisms, oxidative stress and cardiovascular disease in chronic kidney disease patients. *Blood Purification*, **2007**, 25, 210-8	3.1	15
225	Serum albumin: a late-reacting negative acute-phase protein in clinically evident inflammation in dialysis patients. *Nephrology Dialysis Transplantation*, **2005**, 20, 658-9; author reply 659-60	4.3	15
224	Renal function in hypoxaemic chronic obstructive pulmonary disease: effects of long-term oxygen treatment. *Respiratory Medicine*, **2003**, 97, 308-16	4.6	15
223	Adipokines in Chronic Kidney Disease Fat Tissue Gives Nephrologists a Message. *Peritoneal Dialysis International*, **2005**, 25, 340-342	2.8	15
222	Classification of Uremic Toxins and Their Role in Kidney Failure. *Clinical Journal of the American Society of Nephrology: CJASN*, **2021**,	6.9	15
221	Effects of probiotic supplementation on inflammatory biomarkers and uremic toxins in non-dialysis chronic kidney patients: A double-blind, randomized, placebo-controlled trial. *Journal of Functional Foods*, **2018**, 46, 378-383	5.1	15

220	Increased Levels of Modified Advanced Oxidation Protein Products Are Associated with Central and Peripheral Blood Pressure in Peritoneal Dialysis Patients. *Peritoneal Dialysis International*, **2015**, 35, 460-70	2.8	14
219	Effects of hemodiafiltration on uremic inflammation. *Blood Purification*, **2013**, 35 Suppl 1, 11-7	3.1	14
218	Postprandial metabolic response to a fat- and carbohydrate-rich meal in patients with chronic kidney disease. *Nephrology Dialysis Transplantation*, **2011**, 26, 2231-7	4.3	14
217	Cruciferous vegetables: rationale for exploring potential salutary effects of sulforaphane-rich foods in patients with chronic kidney disease. *Nutrition Reviews*, **2021**, 79, 1204-1224	6.4	14
216	Oral health and pro-inflammatory status in end-stage renal disease patients. *Oral Health & Preventive Dentistry*, **2007**, 5, 235-44	1.9	14
215	Nonpharmacologic Strategies to Modulate Nuclear Factor Erythroid 2-related Factor 2 Pathway in Chronic Kidney Disease. *Journal of Renal Nutrition*, **2017**, 27, 282-291	3	13
214	Serum 8-hydroxydeoxyguanosine, a marker of oxidative DNA damage, is associated with mortality independent of inflammation in chronic kidney disease. *European Journal of Internal Medicine*, **2019**, 68, 60-65	3.9	13
213	Methyl Donor Nutrients in Chronic Kidney Disease: Impact on the Epigenetic Landscape. *Journal of Nutrition*, **2019**, 149, 372-380	4.1	13
212	Insights in the regulation of trimetylamine N-oxide production using a comparative biomimetic approach suggest a metabolic switch in hibernating bears. *Scientific Reports*, **2020**, 10, 20323	4.9	13
211	Subclinical atherosclerosis, endothelial function, and serum inflammatory markers in chronic kidney disease stages 3 to 4. *Angiology*, **2014**, 65, 443-9	2.1	13
210	Evaluation of the association of plasma pentraxin 3 levels with type 2 diabetes and diabetic nephropathy in a Malay population. *Journal of Diabetes Research*, **2013**, 2013, 298019	3.9	13
209	Simple advice on lifestyle habits and long-term changes in biomarkers of inflammation and vascular adhesion in healthy middle-aged men. *European Journal of Clinical Nutrition*, **2010**, 64, 1450-6	5.2	13
208	Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients. *Seminars in Dialysis*, **2007**, 20, 523-9	2.5	13
207	Adipokine signaling in the peritoneal dialysis patient. *Contributions To Nephrology*, **2006**, 150, 166-173	1.6	13
206	Bone mineral density and mortality in end-stage renal disease patients. *CKJ: Clinical Kidney Journal*, **2020**, 13, 307-321	4.5	13
205	Hypertensive disorders of pregnancy and the risk of chronic kidney disease: A Swedish registry-based cohort study. *PLoS Medicine*, **2020**, 17, e1003255	11.6	13
204	Nutrients and ageing: what can we learn about ageing interactions from animal biology?. *Current Opinion in Clinical Nutrition and Metabolic Care*, **2016**, 19, 19-25	3.8	13
203	Dietary n-3 polyunsaturated fatty acid intake and all-cause and cardiovascular mortality in adults on hemodialysis: The DIET-HD multinational cohort study. *Clinical Nutrition*, **2019**, 38, 429-437	5.9	13

202	High levels of soluble tumor necrosis factor receptors 1 and 2 and their association with mortality in patients undergoing hemodialysis. *CardioRenal Medicine*, **2015**, 5, 89-95	2.8	12
201	Lung Dysfunction and Mortality in Patients with Chronic Kidney Disease. *Kidney and Blood Pressure Research*, **2018**, 43, 522-535	3.1	12
200	Increased Telomere Attrition After Renal Transplantation-Impact of Antimetabolite Therapy. *Transplantation Direct*, **2016**, 2, e116	2.3	12
199	How can genetics and epigenetics help the nephrologist improve the diagnosis and treatment of chronic kidney disease patients?. *Nephrology Dialysis Transplantation*, **2014**, 29, 972-80	4.3	12
198	Expression of osteoprotegerin in human fat tissue; implications for chronic kidney disease. *European Journal of Clinical Investigation*, **2011**, 41, 498-506	4.6	12
197	Influence of cytokine gene polymorphisms on erythropoetin dose requirements in chronic haemodialysis patients. *Nephrology Dialysis Transplantation*, **2007**, 22, 3586-92	4.3	12
196	Insulin resistance is associated with circulating fibrinogen levels in nondiabetic patients receiving peritoneal dialysis. *Journal of Renal Nutrition*, **2007**, 17, 132-7	3	12
195	Inflammation and Oxidative Stress in Chronic Kidney Disease and Dialysis Patients. *Antioxidants and Redox Signaling*, **2021**, 35, 1426-1448	8.4	12
194	Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients. *BMC Pharmacology & Toxicology*, **2018**, 19, 33	2.6	11
193	Restrictive lung disorder is common in patients with kidney failure and associates with protein-energy wasting, inflammation and cardiovascular disease. *PLoS ONE*, **2018**, 13, e0195585	3.7	11
192	Hypoalbuminemia: a price worth paying for improved dialytic removal of middle-molecular-weight uremic toxins?. *Nephrology Dialysis Transplantation*, **2019**, 34, 901-907	4.3	11
191	Endostatin, Cathepsin S, and Cathepsin L, and Their Association with Inflammatory Markers and Mortality in Patients Undergoing Hemodialysis. *Blood Purification*, **2015**, 39, 259-65	3.1	11
190	Epigenetics and the uremic phenotype: a matter of balance. *Contributions To Nephrology*, **2008**, 161, 55-62	1.6	11
189	Temporal Associations Among Body Mass Index, Fasting Insulin, and Systemic Inflammation: A Systematic Review and Meta-analysis. *JAMA Network Open*, **2021**, 4, e211263	10.4	11
188	Inverse J-shaped relation between coronary arterial calcium density and mortality in advanced chronic kidney disease. *Nephrology Dialysis Transplantation*, **2020**, 35, 1202-1211	4.3	11
187	Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome. *American Journal of Nephrology*, **2021**, 52, 180-189	4.6	11
186	High-density lipoprotein from end-stage renal disease patients exhibits superior cardioprotection and increase in sphingosine-1-phosphate. *European Journal of Clinical Investigation*, **2018**, 48, e12866	4.6	11
185	Recovery scenario and immunity in COVID-19 disease: A new strategy to predict the potential of reinfection. *Journal of Advanced Research*, **2021**, 31, 49-60	13	11

184	Major fractures after initiation of dialysis: Incidence, predictors and association with mortality. *Bone* , **2020**, 133, 115242	4.7	10
183	A cohort study of insulin-like growth factor 1 and mortality in haemodialysis patients. *CKJ: Clinical Kidney Journal*, **2016**, 9, 148-52	4.5	10
182	Low serum testosterone is associated with atherosclerosis in postmenopausal women undergoing hemodialysis. *Clinical and Experimental Nephrology*, **2014**, 18, 499-506	2.5	10
181	Does the uremic milieu affect the epigenotype?. *Journal of Renal Nutrition*, **2009**, 19, 82-5	3	10
180	Understanding the role of genetic polymorphisms in chronic kidney disease. *Pediatric Nephrology*, **2008**, 23, 1941-9	3.2	10
179	C-reactive protein--does it promote vascular disease?. *Nephrology Dialysis Transplantation*, **2006**, 21, 2718-20	4.3	10
178	Bone mineral density at different sites and 5 years mortality in end-stage renal disease patients: A cohort study. *Bone*, **2020**, 130, 115075	4.7	10
177	Data Sharing Under the General Data Protection Regulation: Time to Harmonize Law and Research Ethics?. *Hypertension*, **2021**, 77, 1029-1035	8.5	10
176	Mitochondrial dysfunction and gut microbiota imbalance: An intriguing relationship in chronic kidney disease. *Mitochondrion*, **2019**, 47, 206-209	4.9	10
175	Association of changes in bone mineral parameters with mortality in haemodialysis patients: insights from the ARO cohort. *Nephrology Dialysis Transplantation*, **2020**, 35, 478-487	4.3	10
174	To bee or not to bee? The bee extract propolis as a bioactive compound in the burden of lifestyle diseases. *Nutrition*, **2021**, 83, 111094	4.8	10
173	Serum hepatocyte growth factor is associated with truncal fat mass and increased mortality in chronic kidney disease stage 5 patients with protein-energy wasting. *Nephrology Dialysis Transplantation*, **2015**, 30, 274-82	4.3	9
172	Sevelamer Use in End-Stage Kidney Disease (ESKD) Patients Associates with Poor Vitamin K Status and High Levels of Gut-Derived Uremic Toxins: A Drug-Bug Interaction?. *Toxins*, **2020**, 12,	4.9	9
171	The value of the Brazilian aï fruit as a therapeutic nutritional strategy for chronic kidney disease patients. *International Urology and Nephrology*, **2018**, 50, 2207-2220	2.3	9
170	Clinical determinants and mortality predictability of stearoyl-CoA desaturase-1 activity indices in dialysis patients. *Journal of Internal Medicine*, **2013**, 273, 263-72	10.8	9
169	Current epigenetic aspects the clinical kidney researcher should embrace. *Clinical Science*, **2017**, 131, 1649-1667	6.5	9
168	Novel insights from genetic and epigenetic studies in understanding the complex uraemic phenotype. *Nephrology Dialysis Transplantation*, **2014**, 29, 964-71	4.3	9
167	Determinants of fibroblast growth factor-23 and parathyroid hormone variability in dialysis patients. *American Journal of Nephrology*, **2013**, 37, 462-71	4.6	9

166	Systemic and local inflammation in peritoneal dialysis: mechanisms, biomarkers and effects on outcome. *Contributions To Nephrology*, **2009**, 163, 132-139	1.6	9
165	Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease. *European Journal of Clinical Pharmacology*, **2010**, 66, 269-73	2.8	9
164	Peroxisome proliferator-activated receptor-gamma agonists diminish peritoneal functional and morphological changes induced by bioincompatible peritoneal dialysis solution. *Blood Purification*, **2006**, 24, 575-82	3.1	9
163	Place of genotyping and phenotyping in understanding and potentially modifying outcomes in peritoneal dialysis patients. *Kidney International*, **2006**, S138-45	9.9	9
162	Uremic Toxins and Vascular Calcification-Missing the Forest for All the Trees. *Toxins*, **2020**, 12,	4.9	9
161	Novel insights into the disease transcriptome of human diabetic glomeruli and tubulointerstitium. *Nephrology Dialysis Transplantation*, **2020**, 35, 2059-2072	4.3	9
160	Telomere Attrition and Elongation after Chronic Dialysis Initiation in Patients with End-Stage Renal Disease. *Blood Purification*, **2016**, 41, 25-33	3.1	8
159	A journey from microenvironment to macroenvironment: the role of metaflammation and epigenetic changes in cardiorenal disease. *CKJ: Clinical Kidney Journal*, **2019**, 12, 861-870	4.5	8
158	Kidney biomimicry--a rediscovered scientific field that could provide hope to patients with kidney disease. *Archives of Medical Research*, **2013**, 44, 584-90	6.6	8
157	Plasma Beta-Trace Protein as a Marker of Residual Renal Function: The Effect of Different Hemodialysis Modalities and Intra-Individual Variability over Time. *Kidney and Blood Pressure Research*, **2017**, 42, 877-885	3.1	8
156	Leptin and uremic protein-energy wasting--the axis of eating. *Seminars in Dialysis*, **2009**, 22, 387-90	2.5	8
155	Role of interleukin-1beta in the development of malnutrition in chronic renal failure patients. *Blood Purification*, **2005**, 23, 275-81	3.1	8
154	Beyond the membrane--the role of new PD solutions in enhancing global biocompatibility. *Kidney International*, **2003**, S124-32	9.9	8
153	Genotypic and phenotypic predictors of inflammation in patients with chronic kidney disease. *Nephrology Dialysis Transplantation*, **2016**, 31, 2033-2040	4.3	8
152	Implantation of Autologous Selected Renal Cells in Diabetic Chronic Kidney Disease Stages 3 and 4-Clinical Experience of a "First in Human" Study. *Kidney International Reports*, **2016**, 1, 105-113	4.1	8
151	Systematic review of the nuclear factor erythroid 2-related factor 2 (NRF2) system in human chronic kidney disease: alterations, interventions, and relation to morbidity. *Nephrology Dialysis Transplantation*, **2021**,	4.3	8
150	Inflamed fat and mitochondrial dysfunction in end-stage renal disease links to hypoxia-could curcumin be of benefit?. *Nephrology Dialysis Transplantation*, **2017**, 32, 909-912	4.3	7
149	Bone mineral density of extremities is associated with coronary calcification and biopsy-verified vascular calcification in living-donor renal transplant recipients. *Journal of Bone and Mineral Metabolism*, **2017**, 35, 536-543	2.9	7

148	Can nutritional interventions modulate the activation of the NLRP3 inflammasome in chronic kidney disease?. *Food Research International*, **2020**, 136, 109306	7	7
147	Could Low-Protein Diet Modulate Nrf2 Pathway in Chronic Kidney Disease?. *Journal of Renal Nutrition*, **2018**, 28, 229-234	3	7
146	Premature aging in chronic kidney disease and chronic obstructive pulmonary disease: similarities and differences. *Current Opinion in Clinical Nutrition and Metabolic Care*, **2015**, 18, 528-34	3.8	7
145	Determinants of N-terminal pro-brain natriuretic peptide variation in hemodialysis patients and prediction of survival. *Blood Purification*, **2014**, 37, 138-45	3.1	7
144	Differences in acute metabolism of fructose between hemodialysis patients and healthy subjects. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2013**, 73, 154-60	2	7
143	TNF-levels are not increased in inflamed patients carrying the CCR5 deletion 32. *Cytokine*, **2011**, 53, 16-8	4	7
142	Is UCP2 gene polymorphism associated with decreased resting energy expenditure in nondialyzed chronic kidney disease patients?. *Journal of Renal Nutrition*, **2008**, 18, 489-94	3	7
141	Identifying and Managing Malnutrition Stemming from Different Causes. *Peritoneal Dialysis International*, **2007**, 27, 239-244	2.8	7
140	Chronic inflammation in PD patients. *Contributions To Nephrology*, **2003**, 140, 104-11	1.6	7
139	Pro-neurotensin depends on renal function and is related to all-cause mortality in chronic kidney disease. *European Journal of Endocrinology*, **2020**, 183, 233-244	6.5	7
138	Fractures after kidney transplantation: Incidence, predictors, and association with mortality. *Bone*, **2020**, 140, 115554	4.7	7
137	Elevated Circulating S100A12 Associates with Vascular Disease and Worse Clinical Outcome in Peritoneal Dialysis Patients. *Peritoneal Dialysis International*, **2016**, 36, 269-76	2.8	7
136	Association of Serum Sclerostin with Bone Sclerostin in Chronic Kidney Disease is Lost in Glucocorticoid Treated Patients. *Calcified Tissue International*, **2019**, 104, 214-223	3.9	7
135	Serum concentration and vascular expression of adiponectin are differentially associated with the diabetic calcifying peripheral arteriopathy. *Diabetology and Metabolic Syndrome*, **2019**, 11, 32	5.6	6
134	Dialysis in 2011: Can cardiovascular risk in dialysis patients be decreased?. *Nature Reviews Nephrology*, **2011**, 8, 72-4	14.9	6
133	Statins to Treat Chronic Inflammation in Dialysis Patients Is this Feasible?. *Peritoneal Dialysis International*, **2007**, 27, 254-257	2.8	6
132	Reply to A Molfino et al. *American Journal of Clinical Nutrition*, **2007**, 86, 1551-1553	7	6
131	Use of single-nucleotide polymorphisms in the search for genetic modifiers of the uremic phenotype. *Journal of Renal Nutrition*, **2007**, 17, 17-22	3	6

130	Effect of insulin on renal sodium handling and renal haemodynamics in insulin-dependent (type 1) diabetes mellitus patients. *Acta Diabetologica*, **1995**, 32, 230-4	3.9	6
129	Genetic studies in chronic kidney disease: interpretation and clinical applicability. *Journal of Nephrology*, **2012**, 25, 851-64	4.8	6
128	Phenotypic features of vascular calcification in chronic kidney disease. *Journal of Internal Medicine*, **2020**, 287, 422-434	10.8	6
127	Differences in association of lower bone mineral density with higher coronary calcification in female and male end-stage renal disease patients. *BMC Nephrology*, **2019**, 20, 59	2.7	6
126	Dietary Patterns and Mortality in a Multinational Cohort of Adults Receiving Hemodialysis. *American Journal of Kidney Diseases*, **2020**, 75, 361-372	7.4	6
125	High alkaline phosphatase and low intact parathyroid hormone associate with worse clinical outcome in peritoneal dialysis patients. *Peritoneal Dialysis International*, **2021**, 41, 236-243	2.8	6
124	Serum Glutaredoxin Activity as a Marker of Oxidative Stress in Chronic Kidney Disease: A Pilot Study. *Nephron*, **2018**, 140, 249-256	3.3	6
123	Sclerostin-A Debutant on the Autosomal Dominant Polycystic Kidney Disease Scene?. *Kidney International Reports*, **2017**, 2, 481-485	4.1	5
122	Uremic Toxicity **2013**, 49-77		5
121	Influence of erythropoiesis-stimulating agents on glycated hemoglobin in nondiabetic kidney diseases at the start of dialysis. *American Journal of Nephrology*, **2011**, 33, 17-24	4.6	5
120	Predialysis chronic kidney disease in 2010: Novel targets for slowing CKD progression. *Nature Reviews Nephrology*, **2011**, 7, 65-6	14.9	5
119	Hyperhomocysteinemia, malnutrition, and inflammation in ESRD patients. *Seminars in Nephrology*, **2006**, 26, 14-9	4.8	5
118	Physical activity promotes health also among dialysis patients. *International Journal of Cardiology*, **2000**, 72, 299-300	3.2	5
117	The enigma of increasing serum leptin levels during peritoneal dialysis. *American Journal of Kidney Diseases*, **1999**, 34, 947-50	7.4	5
116	Insulin causes renal vasodilatation independently of renal prostaglandins in healthy humans. *Nephrology Dialysis Transplantation*, **1994**, 9, 1728-33	4.3	5
115	Intestinal alkaline phosphatase modulation by food components: predictive, preventive, and personalized strategies for novel treatment options in chronic kidney disease. *EPMA Journal*, **2020**, 11, 565-579	8.8	5
114	From the distinctive smell to therapeutic effects: Garlic for cardiovascular, hepatic, gut, diabetes and chronic kidney disease. *Clinical Nutrition*, **2021**, 40, 4807-4819	5.9	5
113	Inflammation, Oxidative Stress, and Bone in Chronic Kidney Disease in the Osteoimmunology Era. *Calcified Tissue International*, **2021**, 108, 452-460	3.9	5

112	Role of Uremic Toxins in Early Vascular Ageing and Calcification. *Toxins*, **2021**, 13,	4.9	5
111	Hospitalization and mortality following non-attendance for hemodialysis according to dialysis day of the week: a European cohort study. *BMC Nephrology*, **2020**, 21, 218	2.7	4
110	Different subclasses and isotypes of antibodies against phosphorylcholine in haemodialysis patients: association with mortality. *Clinical and Experimental Immunology*, **2020**, 201, 94-104	6.2	4
109	Risk of long-term renal disease in women with a history of preterm delivery: a population-based cohort study. *BMC Medicine*, **2020**, 18, 66	11.4	4
108	Renal volumetry with magnetic resonance imaging. *Acta Radiologica Open*, **2017**, 6, 2058460117731120	1.2	4
107	Selection of genetic and phenotypic features associated with inflammatory status of patients on dialysis using relaxed linear separability method. *PLoS ONE*, **2014**, 9, e86630	3.7	4
106	Delta-He: a novel marker of inflammation predicting mortality and ESA response in peritoneal dialysis patients. *CKJ: Clinical Kidney Journal*, **2014**, 7, 275-81	4.5	4
105	Three-month variation of plasma pentraxin 3 compared with C-reactive protein, albumin and homocysteine levels in haemodialysis patients. *CKJ: Clinical Kidney Journal*, **2014**, 7, 373-9	4.5	4
104	Immunoglobulin (Ig)M antibodies against oxidized cardiolipin but not native cardiolipin are novel biomarkers in haemodialysis patients, associated negatively with mortality. *Clinical and Experimental Immunology*, **2013**, 174, 441-8	6.2	4
103	Effects of dopamine on leptin release and leptin gene (OB) expression in adipocytes from obese and hypertensive patients. *International Journal of Nephrology and Renovascular Disease*, **2013**, 6, 259-68	2.5	4
102	Cardiovascular Disease in Chronic Kidney Disease **2010**, 935-950		4
101	Hypogonadism in males with chronic kidney disease: another cause of resistance to erythropoiesis-stimulating agents?. *Contributions To Nephrology*, **2012**, 178, 35-39	1.6	4
100	Association between oestrogen receptor alpha gene polymorphism and mortality in female end-stage renal disease patients. *Nephrology Dialysis Transplantation*, **2007**, 22, 2571-7	4.3	4
99	OPTAIhfluence of inflammation/infection on anaemia therapy in haemodialysis patients. *Nephrology Dialysis Transplantation*, **2007**, 22, iii7-iii12	4.3	4
98	Prognostic Value of Copeptin in Chronic Kidney Disease: From General Population to End-Stage Renal Disease. *Current Protein and Peptide Science*, **2017**, 18, 1232-1243	2.8	4
97	A genome-wide association study suggests correlations of common genetic variants with peritoneal solute transfer rates in patients with kidney failure receiving peritoneal dialysis. *Kidney International*, **2021**, 100, 1101-1111	9.9	4
96	Effects of acute fructose loading on levels of serum uric acid-a pilot study. *European Journal of Clinical Investigation*, **2019**, 49, e13040	4.6	4
95	The sweet side of dark chocolate for chronic kidney disease patients. *Clinical Nutrition*, **2021**, 40, 15-26	5.9	4

94	Manipulating the exposome to enable better ageing. *Biochemical Journal*, **2021**, 478, 2889-2898	3.8	4
93	Antibodies against Malondialdehyde in Haemodialysis Patients and Its Association with Clinical Outcomes: Differences between Subclasses and Isotypes. *Journal of Clinical Medicine*, **2020**, 9,	5.1	3
92	Copeptin is independently associated with vascular calcification in chronic kidney disease stage 5. *BMC Nephrology*, **2020**, 21, 43	2.7	3
91	Aortic Valve Calcium Associates with All-Cause Mortality Independent of Coronary Artery Calcium and Inflammation in Patients with End-Stage Renal Disease. *Journal of Clinical Medicine*, **2020**, 9,	5.1	3
90	The One Health concept - the health of humans is intimately linked with the health of animals and a sustainable environment. *Journal of Internal Medicine*, **2020**, 287, 223-225	10.8	3
89	Inflamed fat and mitochondrial dysfunction in end-stage renal disease links to hypoxia-could curcumin be of benefit?. *Nephrology Dialysis Transplantation*, **2017**, 32, 1263	4.3	3
88	Longitudinal genome-wide DNA methylation changes in response to kidney failure replacement therapy.. *Scientific Reports*, **2022**, 12, 470	4.9	3
87	Inflammation as a target for improving health in chronic kidney disease. *F1000 Medicine Reports*, **2010**, 2, 88		3
86	Genetic studies in chronic kidney disease: basic concepts. *Journal of Nephrology*, **2012**, 25, 141-9	4.8	3
85	Cardiovascular Disease Risk Factors in Chronic Kidney Disease: Traditional, Nontraditional, and Uremia-related Threats **2010**, 91-104		3
84	Cinacalcet-induced hypocalcemia in a cohort of European haemodialysis patients: predictors, therapeutic approaches and outcomes. *Journal of Nephrology*, **2020**, 33, 803-816	4.8	3
83	Muscle Mass Assessed by Computed Tomography at the Third Lumbar Vertebra Predicts Patient Survival in Chronic Kidney Disease. *Journal of Renal Nutrition*, **2021**, 31, 342-350	3	3
82	Incidence of Fractures Before and After Dialysis Initiation. *Journal of Bone and Mineral Research*, **2020**, 35, 2372-2380	6.3	3
81	The oxygen cascade in patients treated with hemodialysis and native high-altitude dwellers: lessons from extreme physiology to benefit patients with end-stage renal disease. *American Journal of Physiology - Renal Physiology*, **2021**, 320, F249-F261	4.3	3
80	Socioeconomic position links circulatory microbiota differences with biological age. *Scientific Reports*, **2021**, 11, 12629	4.9	3
79	Potential natural immunization against atherosclerosis in hibernating bears. *Scientific Reports*, **2021** , 11, 12120	4.9	3
78	SARS-COV-2 and biomimetics: What saves the planet will save our health. *Journal of Internal Medicine*, **2021**, 289, 244-246	10.8	3
77	Functional vitamin K insufficiency, vascular calcification and mortality in advanced chronic kidney disease: A cohort study. *PLoS ONE*, **2021**, 16, e0247623	3.7	3

76	Pregnancy-associated plasma protein-A predicts survival in end-stage renal disease-confounding and modifying effects of cardiovascular disease, body composition and inflammation. *Nephrology Dialysis Transplantation*, **2018**, 33, 971-977	4.3	3
75	Lipoprotein(a) in chronic renal disease. *Mineral and Electrolyte Metabolism*, **1996**, 22, 16-21		3
74	Blood-brain barrier and gut barrier dysfunction in chronic kidney disease with a focus on circulating biomarkers and tight junction proteins.. *Scientific Reports*, **2022**, 12, 4414	4.9	3
73	Anorexia and Appetite Stimulants in Chronic Kidney Disease **2013**, 645-657		2
72	Research update for articles published in EJCI in 2011. *European Journal of Clinical Investigation*, **2013**, 43, 1097-1110	4.6	2
71	Short-term treatment with ramipril normalizes renal haemodynamics and the natriuretic response to a sodium load in type 1 diabetic patients with early nephropathy. *Acta Diabetologica*, **1997**, 34, 10-7	3.9	2
70	Lipoprotein lipase 1595 c/g and hepatic lipase -480 c/t polymorphisms--impact on lipid profile in incident dialysis patients. *Blood Purification*, **2008**, 26, 555-60	3.1	2
69	Is hyperhomocysteinemia a contributor to atherosclerosis in chronic kidney disease patients?. *Nephron Clinical Practice*, **2005**, 101, c187-9		2
68	Survival on four compared with three times per week haemodialysis in high ultrafiltration patients: an observational study. *CKJ: Clinical Kidney Journal*, **2021**, 14, 665-672	4.5	2
67	Design and methodology of the Aging Nephropathy Study (AGNES): a prospective cohort study of elderly patients with chronic kidney disease. *BMC Nephrology*, **2020**, 21, 461	2.7	2
66	Patient-Reported Measures and Lifestyle Are Associated With Deterioration in Nutritional Status in CKD Stage 4-5: The EQUAL Cohort Study. *Journal of Renal Nutrition*, **2021**,	3	2
65	Time-dependent lipid profile inversely associates with mortality in hemodialysis patients - independent of inflammation/malnutrition. *Journal of Internal Medicine*, **2021**, 290, 910-921	10.8	2
64	Sparing effect of peritoneal dialysis vs hemodialysis on BMD changes and its impact on mortality. *Journal of Bone and Mineral Metabolism*, **2021**, 39, 260-269	2.9	2
63	Renal function and lipid metabolism are major predictors of circumpapillary retinal nerve fiber layer thickness-the LIFE-Adult Study. *BMC Medicine*, **2021**, 19, 202	11.4	2
62	Role of GDF-15, YKL-40 and MMP 9 in patients with end-stage kidney disease: focus on sex-specific associations with vascular outcomes and all-cause mortality. *Biology of Sex Differences*, **2021**, 12, 50	9.3	2
61	Protein-Energy Malnutrition/Wasting During Peritoneal Dialysis **2009**, 611-647		2
60	Vascular Calcification in Chronic Kidney Disease **2009**, 697-711		2
59	Inhibiting BTB domain and CNC homolog 1 (Bach1) as an alternative to increase Nrf2 activation in chronic diseases.. *Biochimica Et Biophysica Acta - General Subjects*, **2022**, 130129	4	2

58	Do metabolic derangements in end-stage polycystic kidney disease differ versus other primary kidney diseases?. *Nephrology*, **2018**, 23, 31-36	2.2	1
57	Adiponectin in chronic kidney disease: Dr Jekyll and Mr Hyde. *Kidney International*, **2009**, 75, 120-1; author reply 121	9.9	1
56	Conservative treatment of the uremic syndrome. *Seminars in Dialysis*, **2009**, 22, 449-53	2.5	1
55	Telomere biology alterations as a mortality risk factor in CKD. *American Journal of Kidney Diseases*, **2008**, 51, 1076-7	7.4	1
54	Malnutrition in Patients with End-Stage Renal Disease - Anorexia,Cachexia and Catabolism. *Current Nutrition and Food Science*, **2007**, 3, 37-46	0.7	1
53	Emerging Role of Clinical Genetics in CKD.. *Kidney Medicine*, **2022**, 4, 100435	2.8	1
52	Effects of Probiotic Supplementation on Trimethylamine-N-Oxide Plasma Levels in Hemodialysis Patients: a Pilot Study **2019**, 11, 648		1
51	Endocrine Aspects of Chronic Kidney Disease **2011**, 2122-2137		1
50	High-sensitivity troponins in dialysis patients: variation and prognostic value. *CKJ: Clinical Kidney Journal*, **2021**, 14, 1789-1797	4.5	1
49	Methods and rationale of the DISCOVER CKD global observational study. *CKJ: Clinical Kidney Journal*, **2021**, 14, 1570-1578	4.5	1
48	A biomimetic natural sciences approach to understanding the mechanisms of ageing in burden of lifestyle diseases. *Clinical Science*, **2021**, 135, 1251-1272	6.5	1
47	SaO066THE VARIATION IN HOSPITALISATION AND MORTALITY FOLLOWING NON-ATTENDANCE FOR HAEMODIALYSIS ACCORDING TO DIALYSIS DAY OF THE WEEK IN A EUROPEAN COHORT: FURTHER EVIDENCE OF HARM FROM THE TWO-DAY BREAK IN THREE TIMES A WEEK HAEMODIALYSIS. *Nephrology Dialysis Transplantation*, **2018**, 33, i344-i344	4.3	1
46	FP630ASSOCIATION OF FRUIT AND VEGETABLE INTAKE WITH ALL-CAUSE MORTALITY IN HEMODIALYSIS PATIENTS (DIET-HD): A PROSPECTIVE COHORT STUDY. *Nephrology Dialysis Transplantation*, **2018**, 33, i255-i25‘6	4.3	1
45	Observational study of risk factors associated with clinical outcome among elderly kidney transplant recipients in Sweden - a decade of follow-up. *Transplant International*, **2021**, 34, 2363-2370	3	1
44	Premature vascular aging and senescence in chronic kidney disease **2022**, 263-279		1
43	Osteomodulin attenuates smooth muscle cell osteogenic transition in vascular calcification.. *Clinical and Translational Medicine*, **2022**, 12, e682	5.7	1
42	Brazil nut supplementation does not affect trimethylamine-n-oxide plasma levels in patients with coronary artery disease.. *Journal of Food Biochemistry*, **2022**, e14201	3.3	1
41	Research update for articles published in EJCI in 2008. *European Journal of Clinical Investigation*, **2010**, 40, 770-789	4.6	0

40	Inflammation in chronic kidney disease **2022**, 91-105		0
39	Biomimetics provides lessons from nature for contemporary ways to improve human health. *Journal of Clinical and Translational Science*, **2021**, 5, e128	0.4	0
38	Does gestational diabetes increase the risk of maternal kidney disease? A Swedish national cohort study.. *PLoS ONE*, **2022**, 17, e0264992	3.7	0
37	Angiotensin-converting enzyme 2 and Transmembrane protease serine 2 in female and male patients with end-stage kidney disease.. *European Journal of Clinical Investigation*, **2022**, e13786	4.6	0
36	Fermented food: Should patients with cardiometabolic diseases go back to an early neolithic diet?. *Critical Reviews in Food Science and Nutrition*, **2022**, 1-24	11.5	0
35	Vascular Effects of Inflammation and Oxidative Stress in CKD **2015**, 51-59		
34	Pregnancy-associated plasma protein A and mortality in haemodialysis. *European Journal of Clinical Investigation*, **2018**, 48, e12959	4.6	
33	Inflammation in Chronic Kidney Disease **2013**, 79-91		
32	Like total ghrelin, acylated ghrelin is also lower in HD patients with cardiovascular disease. *Kidney International*, **2011**, 80, 783-784	9.9	
31	Association with Helicobacter pylori infection and ghrelin level in hemodialysis patients. *Kidney International*, **2011**, 80, 894	9.9	
30	A calcium-channel blocker, amlodipine, attenuates insulin antinatriuresis but does not modulate insulin-mediated attenuation of cardiovascular reactivity in healthy man. *Nephrology Dialysis Transplantation*, **1997**, 12, 1600-7	4.3	
29	Response to Resistin letters *Kidney International*, **2006**, 70, 1372	9.9	
28	The Influence of C-Hepatitis on C-Reactive Protein in a Cohort of Brazilian Hemodialysis Patients. *Hemodialysis International*, **2004**, 8, 102-102	1.7	
27	Gene Expression Analysis in Inflamed and Non-inflamed Hemodialysis (HD) Patients Using a cDNA Microarray. *Hemodialysis International*, **2003**, 7, 73-104	1.7	
26	Protein-Energy Wasting/Malnutrition and the Inflammatory Response **2020**, 413-429		
25	Obesity in Kidney Disease **2019**, 265-275		
24	Nutritional management of chronic peritoneal dialysis patients **2022**, 593-606		
23	Hormonal status in critically ill patients with or without acute renal failure **1998**, 391-403		

22	Cardiovascular Disease and Inflammation **2009**, 679-695	
21	Secular trends in hip fracture incidence and subsequent mortality in dialysis patients and the general population in Sweden. *Bone*, **2021**, 147, 115909	4.7
20	SP242GLOMERULAR FILTRATION RATE ESTIMATION USING BETA TRACE PROTEIN: EXTERNAL VALIDATION OF THREE EQUATIONS. *Nephrology Dialysis Transplantation*, **2016**, 31, i167-i167	4.3
19	SP286PLASMA BETA TRACE PROTEIN PREDICTS MORTALITY IN CKD: RELATION WITH ENDOTHELIAL DYSFUNCTION. *Nephrology Dialysis Transplantation*, **2016**, 31, i183-i184	4.3
18	MP528SKIN AUTOFLUORESCENCE (SAF), A MARKER OF TISSUE ADVANCED GLYCATED END-PRODUCTS (AGE), AND ARTERIAL STIFFNESS IN PERITONEAL DIALYSIS PATIENTS. *Nephrology Dialysis Transplantation*, **2016**, 31, i516-i516	4.3
17	Inflammation in Chronic Kidney Disease **2019**, 208-223.e9	
16	FP634HIGH ALL CAUSE AND CVD MORTALITY IN AN INCIDENT COHORT OF HEMODIALYSIS PATIENTS WITH LOW SERUM ALBUMIN AND INFLAMMATION. *Nephrology Dialysis Transplantation*, **2018**, 33, i257-i257	4.3
15	SP298HIGHER MEAN CORPUSCULAR VOLUME ASSOCIATES WITH POOR CLINICAL OUTCOME IN CKD5 PATIENTS. *Nephrology Dialysis Transplantation*, **2018**, 33, i444-i444	4.3
14	FP336HIGHER NEUTROPHIL TO LYMPHOCYTE RATIO ASSOCIATES WITH POOR CLINICAL OUTCOME IN CKD5 PATIENTS. *Nephrology Dialysis Transplantation*, **2018**, 33, i144-i145	4.3
13	SaO027CHANGES IN BONE-MINERAL PARAMETERS PREDICT SUBSEQUENT MORTALITY IN HEMODIALYSIS PATIENTS - INSIGHTS FROM THE EUROPEAN ARO-COHORT. *Nephrology Dialysis Transplantation*, **2018**, 33, i326-i326	4.3
12	SP323HIGH FIBRINOGEN LEVELS ARE INDEPENDENTLY ASSOCIATED WITH INCREASED MORTALITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD). *Nephrology Dialysis Transplantation*, **2018**, 33, i452-i452	4.3
11	FP662THE ASSOCIATION OF MEDITERRANEAN AND DASH DIETS WITH MORTALITY IN ADULTS ON HEMODIALYSIS: THE DIET-HD MULTINATIONAL COHORT STUDY. *Nephrology Dialysis Transplantation*, **2018**, 33, i268-i268	4.3
10	Reply letter- critical comments on the impact of curcumin supplementation on expression of inflammatory transcription factors in hemodialysis patients: A pilot randomized, double-blind, controlled study. *Clinical Nutrition*, **2021**, 40, 5521-5522	5.9
9	Cardiovascular Disease and Inflammation **2021**, 1-22	
8	Cellular mechanisms of aging and their impact on the aortic/arterial wall **2022**, 391-405	
7	Hypertensive disorders of pregnancy and the risk of chronic kidney disease: A Swedish registry-based cohort study **2020**, 17, e1003255	
6	Hypertensive disorders of pregnancy and the risk of chronic kidney disease: A Swedish registry-based cohort study **2020**, 17, e1003255	
5	Hypertensive disorders of pregnancy and the risk of chronic kidney disease: A Swedish registry-based cohort study **2020**, 17, e1003255	

4 Hypertensive disorders of pregnancy and the risk of chronic kidney disease: A Swedish registry-based cohort study **2020**, 17, e1003255

3 Hypertensive disorders of pregnancy and the risk of chronic kidney disease: A Swedish registry-based cohort study **2020**, 17, e1003255

2 Hypertensive disorders of pregnancy and the risk of chronic kidney disease: A Swedish registry-based cohort study **2020**, 17, e1003255

1 Resistant Starch Type-2 Supplementation Does Not Decrease Trimethylamine N-Oxide (TMAO) Plasma Level in Hemodialysis Patients. **2022**, 1-8